[go: up one dir, main page]

BRPI0607703A2 - compostos de isoquinolina e métodos de uso dos mesmos - Google Patents

compostos de isoquinolina e métodos de uso dos mesmos

Info

Publication number
BRPI0607703A2
BRPI0607703A2 BRPI0607703-0A BRPI0607703A BRPI0607703A2 BR PI0607703 A2 BRPI0607703 A2 BR PI0607703A2 BR PI0607703 A BRPI0607703 A BR PI0607703A BR PI0607703 A2 BRPI0607703 A2 BR PI0607703A2
Authority
BR
Brazil
Prior art keywords
methods
isoquinoline
isoquinoline compounds
disease
effective amount
Prior art date
Application number
BRPI0607703-0A
Other languages
English (en)
Inventor
Prakash Jagtap
Csaba Szabo
Original Assignee
Inotek Pharmaceutical S Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceutical S Corp filed Critical Inotek Pharmaceutical S Corp
Publication of BRPI0607703A2 publication Critical patent/BRPI0607703A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS DE ISOQUINOLINA E MéTODOS DE USO DOS MESMOS. A presente invenção refere-se a compostos de isoquinolina, composições compreendendo uma quantidade eficaz de um composto de isoquinolina e métodos para o tratamento ou prevenção uma doença inflamatória, uma lesão por reperfusão, diabetes, uma complicação diabética, lesão de reoxigenação resultante de transplante de árgão, uma condição isquêmica, doença de Parkinson, insuficiência renal, uma doença vascular ou câncer compreendendo administração, a um indivíduo que precisa do mesmo, de uma quantidade eficaz de um composto de isoquinolina.
BRPI0607703-0A 2005-02-25 2006-02-15 compostos de isoquinolina e métodos de uso dos mesmos BRPI0607703A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65663805P 2005-02-25 2005-02-25
PCT/US2006/005290 WO2006093666A2 (en) 2005-02-25 2006-02-15 Isoqunoline compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0607703A2 true BRPI0607703A2 (pt) 2009-09-22

Family

ID=36941607

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607703-0A BRPI0607703A2 (pt) 2005-02-25 2006-02-15 compostos de isoquinolina e métodos de uso dos mesmos

Country Status (14)

Country Link
US (1) US20060287313A1 (pt)
EP (1) EP1868607A4 (pt)
JP (1) JP2008531561A (pt)
KR (1) KR20070116016A (pt)
CN (1) CN101252930A (pt)
AU (1) AU2006219022A1 (pt)
BR (1) BRPI0607703A2 (pt)
CA (1) CA2597576A1 (pt)
IL (1) IL185309A0 (pt)
MX (1) MX2007010335A (pt)
NO (1) NO20074737L (pt)
RU (1) RU2007135355A (pt)
WO (1) WO2006093666A2 (pt)
ZA (1) ZA200707083B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
AU2004258801A1 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
JP2007527872A (ja) * 2004-02-26 2007-10-04 イノテック ファーマシューティカルズ コーポレイション イソキノリン誘導体及びその使用方法
PL381014A1 (pl) * 2004-02-26 2007-04-16 Inotek Pharmaceuticals Corporation Tetracykliczne pochodne laktamu i ich zastosowanie
EP1784186A4 (en) * 2004-06-16 2008-05-14 Inotek Pharmaceuticals Corp METHOD FOR TREATING AND PREVENTING EFFECTS AND ENTIRE INCONTINENCE
JP2008531563A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環スルホンアミド化合物およびこれらの使用法
BRPI0606191A2 (pt) * 2005-02-25 2009-06-09 Inotek Pharmaceuticals Corp compostos de amino e carboxamido tetracìclicos e métodos do seu uso
CA2620052A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
MX2009009183A (es) * 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
US10299682B1 (en) 2017-11-22 2019-05-28 Hi Llc Pulsed ultrasound modulated optical tomography with increased optical/ultrasound pulse ratio
US10016137B1 (en) 2017-11-22 2018-07-10 Hi Llc System and method for simultaneously detecting phase modulated optical signals
US10219700B1 (en) 2017-12-15 2019-03-05 Hi Llc Systems and methods for quasi-ballistic photon optical coherence tomography in diffusive scattering media using a lock-in camera detector
US10368752B1 (en) 2018-03-08 2019-08-06 Hi Llc Devices and methods to convert conventional imagers into lock-in cameras
US11857316B2 (en) 2018-05-07 2024-01-02 Hi Llc Non-invasive optical detection system and method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB8828806D0 (en) * 1988-12-09 1989-01-18 Beecham Group Plc Novel compounds
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5597831A (en) * 1991-08-29 1997-01-28 Vufb A.S 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW440562B (en) * 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
US6346536B1 (en) * 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU765625C (en) * 1998-08-24 2004-11-18 Maxim Pharmaceuticals, Inc. Activation and protection of T-cells (CD4+ and CD8+) using an H2 receptor agonist and other T-cell activating agents
US6346535B1 (en) * 1999-01-29 2002-02-12 American Cyanamid Company Fungicidal mixtures
CA2377247A1 (en) * 1999-07-16 2001-01-25 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6277990B1 (en) * 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
WO2001090077A1 (en) * 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2004258801A1 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
JP2007527872A (ja) * 2004-02-26 2007-10-04 イノテック ファーマシューティカルズ コーポレイション イソキノリン誘導体及びその使用方法
PL381014A1 (pl) * 2004-02-26 2007-04-16 Inotek Pharmaceuticals Corporation Tetracykliczne pochodne laktamu i ich zastosowanie
EP1784186A4 (en) * 2004-06-16 2008-05-14 Inotek Pharmaceuticals Corp METHOD FOR TREATING AND PREVENTING EFFECTS AND ENTIRE INCONTINENCE
WO2006039545A2 (en) * 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
JP2008531563A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環スルホンアミド化合物およびこれらの使用法
BRPI0606191A2 (pt) * 2005-02-25 2009-06-09 Inotek Pharmaceuticals Corp compostos de amino e carboxamido tetracìclicos e métodos do seu uso
CA2620052A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof

Also Published As

Publication number Publication date
EP1868607A4 (en) 2008-05-14
IL185309A0 (en) 2008-02-09
ZA200707083B (en) 2008-12-31
WO2006093666A2 (en) 2006-09-08
JP2008531561A (ja) 2008-08-14
EP1868607A2 (en) 2007-12-26
CA2597576A1 (en) 2006-09-08
WO2006093666A3 (en) 2006-10-26
RU2007135355A (ru) 2009-03-27
KR20070116016A (ko) 2007-12-06
AU2006219022A1 (en) 2006-09-08
NO20074737L (no) 2007-11-14
CN101252930A (zh) 2008-08-27
US20060287313A1 (en) 2006-12-21
MX2007010335A (es) 2007-11-06

Similar Documents

Publication Publication Date Title
BRPI0508233A (pt) derivados de isoquinolina e métodos para emprego destes
NO20074737L (no) Isokinolinforbindelser og fremgangsmater for anvendelse derav
BRPI0407757A (pt) derivados de benzamida tetracìclica e métodos de uso dos mesmos
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
BRPI0615096A2 (pt) análogos de indenoisoquinolinona e métodos de uso dos mesmos
BRPI0607240A2 (pt) derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
DK1294769T3 (da) Antistoffer der immunspecifikt binder til BLyS
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
CO6341555A2 (es) Compuestos quimicos 251
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BRPI0606996A2 (pt) combinação de compostos orgánicos, uso da mesma e composição farmacêutica
BRPI0606112B8 (pt) 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
BRPI0606191A2 (pt) compostos de amino e carboxamido tetracìclicos e métodos do seu uso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]